Skip to main content

For Healthcare Professionals

Site Menu

  • Press
  • About Us
  • Global Website
  • Contact
  • English

Search for product, molecule, disease…

User account menu

  • Log in
Home
  • Therapeutic Areas
    • CMR
  • Products
    • Jentadueto®
    • Trajenta®
  • Diseases
    • Diabetes
  • LogIn

Search for product, molecule, disease…

Prof. Cummings (Portsmouth, UK)

  1. Boehringer Ingelheim
  2. HCP Portal
  3. Products
  4. Trajenta®
  5. Resources
  6. Prof. Cummings (Portsmouth, UK)

Prof. Cummings (Portsmouth, UK)

Published 16.11.2018 by Boehringer Ingelheim

Trajenta® consistently lowers HbA1c in line with other DPP4i.

 
Transcript

My experience of Trajenta® is that it consistently lowers HbA1c, typically in the region of 0.6 percent or more and of course if you start with a higher baseline HbA1c, you will see an even greater reduction in HbA1c. And this is very consistent with what we see within the DPP4 class.

RELATED CONTENT

Video of Professor Jodar from Spain speaking about Trajenta
Prof. Jodar (Madrid, Spain)

CAROLINA® cardiovascular safety of linagliptin.

Video of Professor Davies from the UK speaking about Trajenta
Prof. Davies (Leicester, UK)

Linagliptin simplifies T2D treatment.

Video of Professor Frankel from the UK speaking about Trajenta
Prof. Frankel (London, UK)

CV and kidney safety profile of Trajenta®.

Footer menu

  • Sitemap
  • Accessibility Statement
  • Terms of Use
  • Imprint
  • Cookie Policy
  • Privacy Policy
© 2022 Boehringer Ingelheim International GmbH. All rights reserved.
© 2022 Boehringer Ingelheim International GmbH.
All rights reserved.